BMAL1 and Parkinson disease: More recently, Comas et al. (2025) assessed salivary melatonin and oral mucosa Bmal1 expression across four groups: DLB (n = 17), PD (n = 16), iRBD (n = 20), and controls (n = 15), using a 24-h, three-hour interval sampling protocol.